GCM2 and breast carcinoma: Following surgery in breast cancer patients, there is a significant decrease in circulating methylated GCM2, indicating that circulating GCM2 levels in breast cancer patients could serve as novel biomarkers for posttreatment monitoring, aiding in the detection of residual tumors [20].